{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:02:30Z","timestamp":1792512150039,"version":"4.5.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.beem.2024.101910","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T16:09:54Z","timestamp":1719677394000},"page":"101910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess"],"prefix":"10.1016","volume":"38","author":[{"given":"James","family":"MacFarlane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rta","family":"Korbonits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2024.101910_bib1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2024.101910_bib2","first-page":"1","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.beem.2024.101910_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s11154-024-09875-z","article-title":"The changing landscape of acromegaly \u2013 an epidemiological perspective","author":"Rosendal","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.beem.2024.101910_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1530\/EJE-12-0084","article-title":"Predictors of morbidity and mortality in acromegaly: an Italian survey","volume":"167","author":"Arosio","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/cen.12207","article-title":"Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists","volume":"79","author":"Howlett","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101910_bib6","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1210\/jc.2016-1937","article-title":"The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes","volume":"101","author":"Portocarrero-Ortiz","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib7","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/EJE-16-1064","article-title":"Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry","volume":"176","author":"Maione","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2018.00035","article-title":"The growth hormone receptor: mechanism of receptor activation, cell signaling, and physiological aspects","volume":"9","author":"Dehkhoda","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrendo.2010.123","article-title":"The growth hormone receptor: mechanism of activation and clinical implications","volume":"6","author":"Brooks","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101910_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","article-title":"Consensus on criteria for acromegaly diagnosis and remission","volume":"27","author":"Giustina","year":"2024","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101910_bib12","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-024-01397-w","article-title":"Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE)","author":"Giustina","year":"2024","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101910_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/EJE-18-0138","article-title":"A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly","volume":"179","author":"Trainer","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101684","article-title":"Second line treatment of acromegaly: pasireotide or Pegvisomant?","volume":"36","author":"Chiloiro","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib15","first-page":"1","article-title":"Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases","volume":"20","author":"Korbonits","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib16","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/S0021-9258(18)52236-5","article-title":"Mutations in the third alpha-helix of bovine growth hormone dramatically affect its intracellular distribution in vitro and growth enhancement in transgenic mice","volume":"266","author":"Chen","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beem.2024.101910_bib17","doi-asserted-by":"crossref","first-page":"15892","DOI":"10.1016\/S0021-9258(17)40764-2","article-title":"In vitro and in vivo studies of antagonistic effects of human growth hormone analogs","volume":"269","author":"Chen","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beem.2024.101910_bib18","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.1074\/jbc.270.11.6261","article-title":"A 40-amino acid segment of the growth hormone receptor cytoplasmic domain is essential for GH-induced tyrosine-phosphorylated cytosolic proteins","volume":"270","author":"Wang","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beem.2024.101910_bib19","doi-asserted-by":"crossref","unstructured":"Pradhananga S., Wilkinson I., Ross R.J. Pegvisomant: structure and function 2002. https:\/\/doi.org\/10.1677\/jme.0.0290011.","DOI":"10.1677\/jme.0.0290011"},{"issue":"Suppl 2","key":"10.1016\/j.beem.2024.101910_bib20","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1530\/eje.0.148s021","article-title":"Discovery and mechanism of action of pegvisomant","volume":"148","author":"Kopchick","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib21","first-page":"2098","article-title":"Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH","volume":"84","author":"Thorner","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib22","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone\u2013receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2024.101910_bib23","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"Lely","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2024.101910_bib24","unstructured":"Electronic Medicines Compendium. SOMAVERT Summary of product characteristics n.d."},{"key":"10.1016\/j.beem.2024.101910_bib25","unstructured":"Pfizer. SOMAVERT (Pegvisomant) for Injection, for Subcutaneous Use Prescribing Information. 2013."},{"key":"10.1016\/j.beem.2024.101910_bib26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-21-0239","article-title":"More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY","volume":"185","author":"Fleseriu","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY","volume":"179","author":"Buchfelder","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2023.102884","article-title":"Efficacy and safety of pegvisomant in the treatment of acromegaly","volume":"54","author":"Haberbosch","year":"2023","journal-title":"Arch Med Res"},{"key":"10.1016\/j.beem.2024.101910_bib29","first-page":"328","article-title":"Brazilian multicenter study on pegvisomant treatment in acromegaly","volume":"63","author":"Boguszewski","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.20945\/2359-3997000000160","article-title":"Pegvisomant in acromegaly: a multicenter real-life study in Argentina","volume":"63","author":"Basavilbaso","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1507\/endocrj.EJ19-0266","article-title":"Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance","volume":"67","author":"Yamaguchi","year":"2020","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2024.101910_bib32","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40618-022-01980-7","article-title":"Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience","volume":"46","author":"Pirchio","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.beem.2024.101910_bib33","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1210\/jc.2008-2421","article-title":"Guidelines for acromegaly management: an update","volume":"94","author":"Melmed","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib34","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.beem.2024.101910_bib36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5604\/01.3001.0009.5058","article-title":"Acromegaly: the effect of somatostatin analogues on tumour volume shrinkage","volume":"6","author":"Witek","year":"2016","journal-title":"OncoReview"},{"key":"10.1016\/j.beem.2024.101910_bib37","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1210\/jc.2005-2110","article-title":"Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients","volume":"91","author":"Colao","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1210\/er.2010-0002","article-title":"Resistance to somatostatin analogs in acromegaly","volume":"32","author":"Colao","year":"2011","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2024.101910_bib39","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","article-title":"Novel pathway for somatostatin analogs in patients with acromegaly","volume":"24","author":"Gadelha","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib40","first-page":"320","article-title":"Evaluation of the potential of the Ki67 index to predict tumor evolution in patients with pituitary adenoma","volume":"12","author":"Petry","year":"2019","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.beem.2024.101910_bib41","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1210\/jc.2006-2084","article-title":"Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient","volume":"92","author":"Resmini","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib42","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/jc.2003-031344","article-title":"The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro","volume":"89","author":"Hofland","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib43","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1348990","article-title":"Management of pasireotide-induced hyperglycemia in patients with acromegaly: an experts\u2019 consensus statement","volume":"15","author":"St\u00f6rmann","year":"2024","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib45","doi-asserted-by":"crossref","unstructured":"\u00d6berg K., Lamberts S.W.J. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future 2016. https:\/\/doi.org\/10.1530\/ERC-16\u20130151.","DOI":"10.1530\/ERC-16-0151"},{"key":"10.1016\/j.beem.2024.101910_bib46","doi-asserted-by":"crossref","DOI":"10.3171\/2012.4.FOCUS1268","article-title":"Spontaneous and medically induced cerebrospinal fluid leakage in the setting of pituitary adenomas: review of the literature","volume":"32","author":"Lam","year":"2012","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.beem.2024.101910_bib47","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11102-020-01088-2","article-title":"Chiasmal herniation following treatment of pituitary macroadenoma","volume":"24","author":"Tabak","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101910_bib48","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.survophthal.2005.09.001","article-title":"Her vision was tied down","volume":"50","author":"Dorotheo","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.beem.2024.101910_bib49","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s11102-015-0701-2","article-title":"Incidence and prevalence of acromegaly in a large US health plan database","volume":"19","author":"Burton","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101910_bib50","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJM199008023230507","article-title":"Gigantism due to pituitary mammosomatotroph hyperplasia","volume":"323","author":"Moran","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2024.101910_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-017-0836-4","article-title":"Growth hormone-producing pituitary adenomas in childhood and young adulthood: clinical features and outcomes","volume":"21","author":"Nagata","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101910_bib52","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1530\/ERC-15-0320","article-title":"Clinical and genetic characterization of pituitary Gigantism: an international collaborative study in 208 patients","volume":"22","author":"Rostomyan","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101910_bib53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3171\/2014.3.JNS131532","article-title":"Morbidity of repeat transsphenoidal surgery assessed in more than 1000 operations","volume":"121","author":"Jahangiri","year":"2014","journal-title":"J Neurosurg"},{"key":"10.1016\/j.beem.2024.101910_bib54","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13014-023-02324-2","article-title":"Neurocognition and mean radiotherapy dose to vulnerable brain structures: new organs at risk?","volume":"18","author":"S\u00f6derstr\u00f6m","year":"2023","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.beem.2024.101910_bib55","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40478-016-0328-1","article-title":"Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study","volume":"4","author":"Iacovazzo","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.beem.2024.101910_bib56","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1530\/ERC-15-0038","article-title":"X-linked acrogigantism syndrome: clinical profile and therapeutic responses","volume":"22","author":"Beckers","year":"2015","journal-title":"Endocr-Relat Cancer"},{"key":"10.1016\/j.beem.2024.101910_bib57","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1210\/jc.2013-3826","article-title":"Acromegaly and McCune-Albright syndrome","volume":"99","author":"Salenave","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib58","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/79238","article-title":"Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex","volume":"26","author":"Kirschner","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.beem.2024.101910_bib59","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1159\/000327831","article-title":"Clinical features and treatment of pediatric somatotropinoma: case study of an aggressive tumor due to a new AIP mutation and extensive literature review","volume":"75","author":"Personnier","year":"2011","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.beem.2024.101910_bib60","first-page":"385","article-title":"Pituitary gigantism: a case series from Hospital de San Jos\u00e9 (Bogot\u00e1, Colombia)","volume":"63","author":"Garc\u00eda","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib61","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000488856","article-title":"Resistant paediatric somatotropinomas due to AIP mutations: role of pegvisomant","volume":"90","author":"Joshi","year":"2018","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.beem.2024.101910_bib62","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11102-016-0732-3","article-title":"Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening","volume":"19","author":"Mangupli","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101910_bib63","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1210\/jc.2019-00432","article-title":"Surgery, octreotide, temozolomide, bevacizumab, radiotherapy, and pegvisomant treatment of an AIP mutation-positive child","volume":"104","author":"Dutta","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib64","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1210\/jc.2013-3826","article-title":"Acromegaly and McCune-Albright syndrome","volume":"99","author":"Salenave","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib65","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/cen.13722","article-title":"Growth hormone\u2014Insulin\u2010like growth factor 1 axis hyperactivity on bone fibrous dysplasia in McCune\u2010Albright syndrome","volume":"89","author":"Tessaris","year":"2018","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib66","article-title":"Effective long-term pediatric pegvisomant monotherapy to final height in X-linked Acrogigantism","volume":"1","author":"Burren","year":"2023","journal-title":"JCEM Case Rep"},{"key":"10.1016\/j.beem.2024.101910_bib67","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12020-015-0804-6","article-title":"Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome","volume":"51","author":"Naves","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101910_bib68","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2015-4366","article-title":"Somatic GPR101 duplication causing X-linked Acrogigantism (XLAG)-diagnosis and management","volume":"101","author":"Rodd","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib69","first-page":"1","article-title":"Pegvisomant treatment in a 4-year-old girl with neurofibromatosis type 1","volume":"65","author":"Main","year":"2006","journal-title":"Horm Res"},{"key":"10.1016\/j.beem.2024.101910_bib70","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ecl.2020.06.002","article-title":"Advances in the imaging of pituitary tumors","volume":"49","author":"MacFarlane","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.beem.2024.101910_bib71","doi-asserted-by":"crossref","unstructured":"Bakker L.E.H., Verstegen M.J.T., Manole D.C., et al. 18F-fluoro-ethyl-tyrosine PET co-registered with MRI in patients with persisting acromegaly. Clinical Endocrinology n.d.;n\/a. https:\/\/doi.org\/10.1111\/cen.15079.","DOI":"10.1111\/cen.15079"},{"key":"10.1016\/j.beem.2024.101910_bib72","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ejendo\/lvae028","article-title":"Real-world experience with 11C-methionine positron emission tomography in the management of acromegaly","volume":"190","author":"Haberbosch","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib73","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11102-019-00943-1","article-title":"Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study","volume":"22","author":"C\u00e1mara","year":"2019","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101910_bib74","doi-asserted-by":"crossref","first-page":"318","DOI":"10.20945\/2359-3997000000163","article-title":"Pegvisomant for acromegaly: does it always works?","volume":"63","author":"Neggers","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib75","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s11102-015-0673-2","article-title":"Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort","volume":"18","author":"Sievers","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101910_bib76","doi-asserted-by":"crossref","unstructured":"Giampietro A., Chiloiro S., Urbani C., et al. Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis 2024. https:\/\/doi.org\/10.1530\/EC-23\u20130247.","DOI":"10.1530\/EC-23-0247"},{"key":"10.1016\/j.beem.2024.101910_bib77","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/BF03347452","article-title":"Pegvisomant in acromegaly: why, when, how","volume":"30","author":"Colao","year":"2007","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.beem.2024.101910_bib78","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1530\/EJE-16-0008","article-title":"Treatment with high doses of pegvisomant in 56 patients with acromegaly: experience from ACROSTUDY","volume":"175","author":"van der Lely","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib79","article-title":"Beware of epistaxis: fatal pseudoaneurysm rupture 30 years after treatment of acromegaly","volume":"17","author":"Carreira","year":"2024","journal-title":"BMJ Case Rep CP"},{"key":"10.1016\/j.beem.2024.101910_bib80","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1530\/EJE-08-0990","article-title":"Successful use of weekly pegvisomant administration in patients with acromegaly","volume":"161","author":"Higham","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib81","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1530\/EJE-15-1150","article-title":"What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?","volume":"174","author":"Muhammad","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib82","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1530\/EJE-14-0844","article-title":"Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey","volume":"172","author":"Sch\u00f6fl","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib83","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12902-020-0545-2","article-title":"Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies","volume":"20","author":"Ma","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.beem.2024.101910_bib84","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EJE-10-0969","article-title":"Hypothesis: extra-hepatic acromegaly: a new paradigm?","volume":"164","author":"Neggers","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib85","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s12020-016-0995-5","article-title":"Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly","volume":"55","author":"Auriemma","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101910_bib86","doi-asserted-by":"crossref","first-page":"646","DOI":"10.20945\/2359-3997000000195","article-title":"The position of combined medical treatment in acromegaly","volume":"63","author":"Coopmans","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib87","doi-asserted-by":"crossref","first-page":"e3236","DOI":"10.1210\/clinem\/dgaa444","article-title":"Cost-effectiveness and efficacy of a novel combination Regimen in acromegaly: a prospective, randomized trial","volume":"105","author":"Bonert","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib88","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1210\/jc.2008-0669","article-title":"Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant","volume":"93","author":"Neggers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib89","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1210\/jc.2011-0654","article-title":"Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients","volume":"96","author":"Madsen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib90","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1210\/jc.2011-2603","article-title":"Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial","volume":"97","author":"Higham","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib91","unstructured":"Specialised Commissioning Team. Clinical Commisioning Policy: Pegvisomant for acromegaly as a a third-line treatment (adults) 2016."},{"key":"10.1016\/j.beem.2024.101910_bib92","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1472-6823-9-20","article-title":"Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation","volume":"9","author":"Moore","year":"2009","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.beem.2024.101910_bib93","first-page":"105","article-title":"Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain","volume":"20","author":"Peral","year":"2020","journal-title":"Expert Rev Pharm Outcomes Res"},{"key":"10.1016\/j.beem.2024.101910_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.745843","article-title":"Cost-utility of acromegaly pharmacological treatments in a French context","volume":"12","author":"Brue","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib95","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s11102-021-01193-w","article-title":"Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length","volume":"25","author":"Cocchiara","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101910_bib96","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1210\/jc.2009-2547","article-title":"Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert\u2019s syndrome","volume":"95","author":"Bernabeu","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib97","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1590\/S1807-59322010000900018","article-title":"Lipodystrophy during pegvisomant therapy: a case report and review of the literature","volume":"65","author":"Buyuktas","year":"2010","journal-title":"Clinics"},{"key":"10.1016\/j.beem.2024.101910_bib98","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1210\/jc.2008-0833","article-title":"Lipodystrophy in patients with acromegaly receiving pegvisomant","volume":"93","author":"Bonert","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib99","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s12020-014-0508-3","article-title":"Pregnancy in acromegaly patients treated with pegvisomant","volume":"49","author":"van der Lely","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101910_bib100","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s11102-020-01050-2","article-title":"Preconception use of pegvisomant alone or as combination therapy for acromegaly: a case series and review of the literature","volume":"23","author":"Guarda","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101910_bib101","first-page":"827","article-title":"The effects of growth hormone on therapy resistance in cancer","volume":"2","author":"Basu","year":"2019","journal-title":"Cdr"},{"key":"10.1016\/j.beem.2024.101910_bib102","unstructured":"GH and IGF1 in cancer therapy resistance in: Endocrine-Related Cancer Volume 30 Issue 9 (2023) n.d. https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/30\/9\/ERC-22\u20130414.xml (Accessed June 23, 2024)."},{"key":"10.1016\/j.beem.2024.101910_bib103","doi-asserted-by":"crossref","first-page":"A648","DOI":"10.1210\/jendso\/bvab048.1321","article-title":"Safety and efficacy of pegvisomant in pediatric growth hormone excess","volume":"5","author":"Tatsi","year":"2021","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.beem.2024.101910_bib104","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2015-4366","article-title":"Somatic GPR101 duplication causing X-linked acrogigantism (XLAG)\u2014diagnosis and management","volume":"101","author":"Rodd","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib105","article-title":"Pegvisomant is More Effective in Stunting Growth than Somatostatin Analogs in Childhood Acromegaly\/Gigantism","volume":"vol. 86","author":"Thomas-Teinturier","year":"2016"},{"key":"10.1016\/j.beem.2024.101910_bib106","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1210\/jc.2007-2283","article-title":"Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant","volume":"93","author":"Goldenberg","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib107","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000271919","article-title":"Eight-year follow-up of a child with a GH\/Prolactin-secreting adenoma: efficacy of pegvisomant therapy","volume":"73","author":"Bergamaschi","year":"2010","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.beem.2024.101910_bib108","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/eje.1.01956","article-title":"Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl","volume":"153","author":"Rix","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101910_bib109","article-title":"Growth Hormone (GH) Secreting Pituitary Adenomas in Paediatric Practice: 5 Cases Over 20 Years in a Single Tertiary NeuroEndocrine Centre","volume":"vol. 89","author":"Brooker","year":"2018"},{"key":"10.1016\/j.beem.2024.101910_bib110","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11102-007-0060-8","article-title":"Management of type 2 diabetes mellitus associated with pituitary gigantism","volume":"10","author":"Ali","year":"2007","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101910_bib111","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12020-015-0804-6","article-title":"Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome","volume":"51","author":"Naves","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101910_bib112","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1210\/jc.2013-3826","article-title":"Acromegaly and McCune-Albright syndrome","volume":"99","author":"Salenave","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101910_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1345363","article-title":"Case report: management of pediatric gigantism caused by the TADopathy, X-linked acrogigantism","volume":"15","author":"Caruso","year":"2024","journal-title":"Front Endocrinol"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T22:48:26Z","timestamp":1721342906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X24000642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":113,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1521690X24000642"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2024.101910","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2024.101910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101910"}}